about
Proinflammatory adaptive cytokine and shed tumor necrosis factor receptor levels are elevated preceding systemic lupus erythematosus disease flareAnti-inflammatory effects of the neurotransmitter agonist Honokiol in a mouse model of allergic asthma.High Affinity Antibodies against Influenza Characterize the Plasmablast Response in SLE Patients After Vaccination.Association of IFIH1 and pro-inflammatory mediators: Potential new clues in SLE-associated pathogenesis.Genetics of Lupus Nephritis: Clinical Implications.Genetic susceptibility to lupus: the biological basis of genetic risk found in B cell signaling pathways.Impact of heart rate variability, a marker for cardiac health, on lupus disease activity.Autoantibody-Positive Healthy Individuals Display Unique Immune Profiles That May Regulate AutoimmunityFunctional roles for T cell CD40 in infection and autoimmune disease: the role of CD40 in lymphocyte homeostasis.Clinical and serological features distinguish patients with incomplete lupus classification from systemic lupus erythematosus patients and controls.Dysregulation of innate and adaptive serum mediators precedes systemic lupus erythematosus classification and improves prognostic accuracy of autoantibodies.Systemic lupus erythematosus biomarkers: the challenging quest.Honokiol, a natural plant product, inhibits inflammatory signals and alleviates inflammatory arthritis.A costimulatory function for T cell CD40.Cooperation between TNF receptor-associated factors 1 and 2 in CD40 signaling.Discerning Risk of Disease Transition in Relatives of Systemic Lupus Erythematosus Patients Utilizing Soluble Mediators and Clinical Features.Role of tumor necrosis factor (TNF) receptor-associated factor 2 (TRAF2) in distinct and overlapping CD40 and TNF receptor 2/CD120b-mediated B lymphocyte activation.Combined role of vitamin D status and CYP24A1 in the transition to systemic lupus erythematosus.Altered type II interferon precedes autoantibody accrual and elevated type I interferon activity prior to systemic lupus erythematosus classification.Pathways of impending disease flare in African-American systemic lupus erythematosus patients.Unique clinical characteristics, autoantibodies and medication use in Native American patients with systemic lupus erythematosus.Expression of the Cytoplasmic Tail of LMP1 in Mice Induces Hyperactivation of B Lymphocytes and Disordered Lymphoid ArchitectureEthanol Ingestion Inhibits Cell-Mediated Immune Responses of Unprimed T-Cell Receptor Transgenic Mice
P50
Q34025881-66F0750B-C9A4-4D93-96CD-F39CA331627CQ35400401-C56DFCC4-D6CE-4B05-B9D3-D73F1E3DBE65Q35624357-5D1077F4-0080-483A-BBA8-67E6DB588FE0Q36289499-5D2BB350-B4DD-48E3-8E2C-59AF4EE3757CQ36300008-84B16AAF-6FD5-4A22-8776-AB2D5006A74FQ37107525-EE9ED298-FFE3-4207-8B1F-653F0083EFD8Q37230849-B2DD84B6-02AF-4467-836F-73B32882F5C3Q37297665-F8F1823B-14C8-43E8-8842-42D2E241D13BQ37524800-4059E473-ED3D-44D6-90BE-6F52393BA494Q38766335-4004C311-D2E4-448D-9D4C-FEFE07AC7417Q38806513-A9A39129-97BB-40D3-8CFB-30FCF23B02D4Q39053118-EA7CE16C-55A1-40AB-BADE-46D6FF185612Q40110013-2F338401-6037-4190-820C-6B50C49645A6Q40187343-DC28B415-FA73-4A9F-8E3D-844589D6D87AQ40290683-D3A24116-8CA4-4600-946D-6642C4B6576CQ40468255-38BFCCE6-9D52-456D-9424-DCF0BAD46DEDQ40504183-9373D216-B3B1-4F98-99E0-EB0664293A87Q40709092-48532F79-A33A-4AE0-9B8A-9284378BCA76Q40795030-9B1B89E5-1B74-49BD-B593-234B2FB1CC69Q50910971-BF2905E0-9C57-4EB2-8D26-E4831DFF87D0Q52659257-34614A82-0B6F-4C5A-83BE-4E24AC21A64AQ57791640-FFC3983B-B344-4907-BF33-F142829B61C5Q63213574-A2CC1B03-8937-4CB3-A1F5-BA65B8E0B9C5
P50
description
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Melissa E Munroe
@ast
Melissa E Munroe
@en
Melissa E Munroe
@es
Melissa E Munroe
@nl
Melissa E Munroe
@sl
type
label
Melissa E Munroe
@ast
Melissa E Munroe
@en
Melissa E Munroe
@es
Melissa E Munroe
@nl
Melissa E Munroe
@sl
prefLabel
Melissa E Munroe
@ast
Melissa E Munroe
@en
Melissa E Munroe
@es
Melissa E Munroe
@nl
Melissa E Munroe
@sl
P106
P21
P31
P496
0000-0002-6933-9745